Autoimmunity After Checkpoint Blockade

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
Abramson Cancer Center at Penn Medicine
Study ID
NCT04119713
Status
Recruiting
Apply to this trial

Conditions

  • Autoimmunity
  • Cancer
  • Immunotoxicity
  • Oncology

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The purpose of this study is to better understand how the treatment of cancer with immune checkpoint inhibitors (ICI) leads to the development of autoimmunity. Specifically, we wish to understand the genetics and immune system features that cause a subset of cancer patients treated with checkpoint inhibitor therapy to develop an immune-related adverse event (irAE).

Key Dates

Start date
Feb 24, 2020
Status verified
Jan 2026
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026

Study Design

Enrollment
600 participants (estimated)

Arms

  • Arm: Study Population
    Adult patients with a diagnosis of cancer receiving checkpoint inhibitor therapy at the University of Pennsylvania's Abramson Cancer Center (ACC).

Primary Outcome Measure

The phenotype and function of peripheral blood cells (i.e., CD4+ T cells, CD8+ T cells, B cells, myeloid cells) characteristic to patients receiving checkpoint inhibitor therapy. [ Time Frame: 6 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Pennsylvania - Abramson Cancer CenterPhiladelphiaPennsylvania19104
Kyra J Sacksith

Find similar trials in Philadelphia, PA

By research site
University of Pennsylvania - Abramson Cancer Center· Philadelphia, PA

Related Studies